ERBA Diagnostics (OTCMKTS:ERBA) is a global provider of in vitro diagnostic solutions, offering a comprehensive portfolio of clinical laboratory instruments, reagents and software. The company’s product suite is designed to support clinical chemistry, immunodiagnostics, haematology and molecular diagnostics testing, enabling healthcare providers to deliver accurate and timely results for patient diagnosis and monitoring.
The company’s core offerings include fully automated chemistry analyzers, ELISA and chemiluminescence immunoassay systems, haematology analyzers and molecular testing platforms. ERBA Diagnostics also supplies a broad range of reagents and quality control materials, as well as laboratory information management systems (LIMS) that streamline workflow and data integration in diagnostic laboratories.
ERBA Diagnostics serves a network of distributors and end users across multiple regions, with a presence in Asia, Eastern Europe, Latin America, the Middle East and Africa. By leveraging its global footprint, the company delivers localized sales, technical support and training services to hospitals, reference laboratories and independent testing facilities.
Part of the ErbaMannheim Group, ERBA Diagnostics combines over three decades of industry experience with ongoing investment in research and development. The company places a strong emphasis on regulatory compliance and quality assurance, maintaining certifications and adhering to international standards to support the needs of clinical laboratories worldwide.
AI Generated. May Contain Errors.
